OpenEvidence
面向医生的循证医学AI搜索平台
成立年份2022
国家United States
一级垂类Healthcare
二级垂类Medical Search
AI Native：confirmed。AI检索与生成是核心产品 · 官网
1. 商业数据
收入历史
| 口径 | 金额 | 期间 | 属性 | 日期 | 状态 | 置信度 |
|---|---|---|---|---|---|---|
| Revenue Run-rate | $150m | point_in_time | Est. | 2025-12-31 | reported | 0.6 |
| Revenue | $50m | calendar_year | Est. | 2025-12-31 | reported | 0.6 |
融资与估值历史
| 估值 | 类型 | 轮次 | 属性 | 日期 | 状态 | 置信度 |
|---|---|---|---|---|---|---|
| $12.0bn | reported_valuation | Series D | Est. | 2026-01-21 | reported | 0.75 |
| $6.0bn | funding_round_unspecified | Series C | Est. | 2025-11-28 | reported | 0.6 |
2. 模型与技术路线
未披露
3. 算力与云
| 供应商 | 类型 | 用途 | 日期 | 状态 | 置信度 |
|---|---|---|---|---|---|
| Baseten | neocloud | inference_compute | 2025-09-17 | reported | 0.75 |
4. 来源与证据
收入：revenue_run_rate reported · 置信度 0.6
OpenEvidence revenue, valuation & funding · 2026-05-20 · 原始来源
Sacra estimates [OpenEvidence](https://sacra.com/c/openevidence/) hit $150 million in annualized revenue in 2025, up 1,803% from $7.9 million in 2024, with reported 90% gross margins.
估值估算：reported_valuation reported · 置信度 0.75
OpenEvidence hits $12B valuation, with new round led by Thrive, DST | TechCrunch · 2026-01-21 · 原始来源
On Wednesday, the startup [announced](https://www.businesswire.com/news/home/20260121029132/en/OpenEvidence-Raises-%24250-Million-to-Build-Medical-Superintelligence-for-Doctors) that it raised an additional $250 million in Series D funding at a $12 billion valuation, co-led by Thrive Capital and DST.
估值估算：funding_round_unspecified reported · 置信度 0.6
OpenEvidence Revenue 2025: $50M ARR, $6B Valuation · 2025-11-28 · 原始来源
OpenEvidence reached a $6B valuation in 2025, set during its Series C round.
收入：revenue reported · 置信度 0.6
OpenEvidence Revenue 2025: $50M ARR, $6B Valuation · 2025-11-28 · 原始来源
In 2025, OpenEvidence's revenue reached $50M. Since its launch in 2021, OpenEvidence has shown consistent revenue growth.
算力/云：Baseten reported · 置信度 0.75
OpenEvidence delivers instant, accurate medical information with the Baseten Inference Stack · 2025-09-17 · 原始来源
When the OpenEvidence team first connected with Baseten, they were powering inference in-house. As the scale of the product expanded to hundreds of thousands of clinicians around the world, managing and optimizing inference infrastructure took more and more time away from focus on where OpenEvidence uniquely shines: building best-in-class tools for physicians.